Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC.

There was a nonsignificant trend toward superior RFS in the subset of patients with a pathologic response (tumor necrosis ≥ 70%) with neoadjuvant immunotherapy.

also in 5,406 other papers

Upfront resectability status was negatively prognostic for RFS (HR 4.39, 95% CI, 0.82–23.53) but did not reach statistical significance.

also in 111,027 other papers